NR1H4 and metabolic dysfunction-associated steatohepatitis: The FLIGHT-FXR study will assess its safety, tolerability, and efficacy on markers of liver inflammation in patients with NASH39, while the second one (TANDEM study) will evaluate its efficacy in combination with cenicriviroc in patients with NASH and liver fibrosis40.